| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/05/2004 | CA2513432A1 Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist |
| 08/05/2004 | CA2513418A1 Microparticles comprising polynucleotide adsorbed on the surface of or entrapped within the microparticles |
| 08/05/2004 | CA2513331A1 Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
| 08/05/2004 | CA2513006A1 Drug particles obtained by freezing onto a cold surface |
| 08/05/2004 | CA2513004A1 Aptamer therapeutics useful in ocular pharmacotherapy |
| 08/05/2004 | CA2512899A1 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| 08/05/2004 | CA2512786A1 Methods and dosage forms with modified viscosity layers |
| 08/05/2004 | CA2512736A1 Novel compounds |
| 08/05/2004 | CA2512546A1 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 08/05/2004 | CA2512319A1 Compositions and methods for combination antiviral therapy |
| 08/05/2004 | CA2512136A1 Thienopyridazinones and their use in modulation of autoimmune disease |
| 08/05/2004 | CA2512043A1 Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| 08/05/2004 | CA2511948A1 Combination of cinnarizine and dimenhydrinate for the treatment of vertigo as a consequence of vestibular neuropathy |
| 08/05/2004 | CA2511491A1 Androgen receptor antagonists |
| 08/05/2004 | CA2511089A1 Androgen receptor antagonists |
| 08/05/2004 | CA2509456A1 Substituted alkyl amido piperidines |
| 08/05/2004 | CA2509259A1 Sustained-release preparations and method for producing the same |
| 08/05/2004 | CA2501485A1 Compositions for the reduction of hair growth |
| 08/05/2004 | CA2488677A1 Method of inhibiting prostate cancer cell proliferation |
| 08/05/2004 | CA2485565A1 Inhibitors and methods of use thereof |
| 08/04/2004 | EP1443438A1 Dna providing system |
| 08/04/2004 | EP1443112A2 Macrophage activating factors derived from cloned vitamin D binding protein |
| 08/04/2004 | EP1443110A2 Human VEGF-specific antisense oligonucleotides |
| 08/04/2004 | EP1443108A2 Processes for preparing reconstructed skin supplemented in ceramid 7 and/or 5.5, composition based on lamellar lipid vesicles comprising a derivative of ceramid 7 and/or 5.5 and use thereof |
| 08/04/2004 | EP1443051A2 Sugar modified oligonucleotides that detect and modulate gene expression |
| 08/04/2004 | EP1443043A2 Highly selective process for the preparation of enantiomerically pure phenyl-substituted 1,4-dihydropyridine-3,5-dicarboxylic acid derivatives |
| 08/04/2004 | EP1443041A1 5-amidino-2-hydroxybenzenesulfonamide derivatives, medicinal compositions containing the same, medicinal use thereof and intermediates in the production thereof |
| 08/04/2004 | EP1442753A1 Composition for the prevention of indwelling device related infection |
| 08/04/2004 | EP1442747A1 Superoxide dismutase and mimetics thereof |
| 08/04/2004 | EP1442746A1 Stable solid formulation of enalapril salt and process for preparation thereof |
| 08/04/2004 | EP1442745A1 Orally administrable opioid formulations having extended duration of effect |
| 08/04/2004 | EP1442744A2 Use of EP4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer |
| 08/04/2004 | EP1442743A1 Medicament comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin converting enzyme (ACE) for use in the treatment of neurodegenerative diseases |
| 08/04/2004 | EP1442742A1 Apoptosis inducer and method of screening for a substance inhibiting acylated homoserine lactone |
| 08/04/2004 | EP1442741A1 Compositions and methods for treating obesity |
| 08/04/2004 | EP1442740A1 Use of N-arylmethylene ethylenediamine triacetates, N-arylmethylene iminodiacetates or N, N'-diarylmethylene ethylenediamine diacetates as NO donors |
| 08/04/2004 | EP1442739A1 Use of mono- or diesters of cinnamic acid or of one of its derivatives and vitamin C, as an NO donor |
| 08/04/2004 | EP1442738A1 Dermatological cosmetic composition comprising vitamin K1 oxide |
| 08/04/2004 | EP1442737A2 Use of a (dihydro)jasmonic acid derivative for dry skin treatment |
| 08/04/2004 | EP1442664A1 A method for supplying biovailable methionine to a cow |
| 08/04/2004 | EP1442140A2 Antisense modulation of insulin-like growth factor binding protein 5 expression |
| 08/04/2004 | EP1442133A2 Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 |
| 08/04/2004 | EP1442132A2 Methods for the treatment of osteoarthritis and compositions thereof |
| 08/04/2004 | EP1442125A2 Chimeric viral vectors for gene therapy |
| 08/04/2004 | EP1442066A1 Compositions comprising chitosan in the form of nano-sized fibres |
| 08/04/2004 | EP1442062A2 Methods for the treatment of carcinoma |
| 08/04/2004 | EP1442060A2 A novel g protein-coupled receptor, gave 10 |
| 08/04/2004 | EP1442050A2 Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 08/04/2004 | EP1442049A2 Substituted amino ketone compounds |
| 08/04/2004 | EP1442044A1 A process for the preparation of cefixime via alkyl-or aryl-sulfonates |
| 08/04/2004 | EP1442043A1 Condensed pyrimidone derivatives as lp-pla2 inhibitors for the treatment of atherosclerosis |
| 08/04/2004 | EP1442042A1 Polycyclic guanine derivative phosphodiesterase v inhibitors |
| 08/04/2004 | EP1442041A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease |
| 08/04/2004 | EP1442040A1 Bridged bicycle (1,4) benzodiazepine vasopressin receptor antagonists |
| 08/04/2004 | EP1442039A1 Pyrimido (4,5-b) indole derivatives |
| 08/04/2004 | EP1442038A2 Crystalline forms of carbapenem antibiotics and methods of preparation |
| 08/04/2004 | EP1442037A1 Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands |
| 08/04/2004 | EP1442036A2 Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1 |
| 08/04/2004 | EP1442035A1 Process for the preparation of 4- (8-chloro-5, 6-dihydro-11h-benzo-[5,6]-cyclohepta-[1,2-b]-pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester (loratadine) |
| 08/04/2004 | EP1442034A1 Benzimidazole derivatives and their use as kdr protein kinase inhibitors |
| 08/04/2004 | EP1442033A1 Omega-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists |
| 08/04/2004 | EP1442032A1 Heterocyclic retinoid compounds |
| 08/04/2004 | EP1442030A1 Thiopene- amd thiazolesulfonamides as antineoplastic agents |
| 08/04/2004 | EP1442028A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| 08/04/2004 | EP1442026A1 Triazole derivatives as cyclooxygenase (cox) inhibitors |
| 08/04/2004 | EP1442025A1 Pyrimidinones as melanin concentrating hormone receptor 1 |
| 08/04/2004 | EP1442024A1 AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS |
| 08/04/2004 | EP1442023A1 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist |
| 08/04/2004 | EP1442022A2 Polyamide modulators of cox2 transcription |
| 08/04/2004 | EP1442021A1 Substituted 1h-quinolin-2-one compounds |
| 08/04/2004 | EP1442020A1 Heterocyclic derivatives of glycinamide and their medical use |
| 08/04/2004 | EP1442019A1 Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
| 08/04/2004 | EP1442018A1 Novel anticancer compounds |
| 08/04/2004 | EP1442017A1 Preparation of benzosuberonylpiperidine compounds |
| 08/04/2004 | EP1442016A1 1h-indole derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 08/04/2004 | EP1442015A1 Use of 2-acylindoles in the treatment of tumors |
| 08/04/2004 | EP1442008A1 Unsaturated 1-amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists |
| 08/04/2004 | EP1441785A2 Improved method for generating an aerosol |
| 08/04/2004 | EP1441772A2 Polymer conjugates of protein kinase c inhibitors |
| 08/04/2004 | EP1441770A1 Vaginally administerd anti-dysrhythmic agents for treating pelvic pain and infertility |
| 08/04/2004 | EP1441769A1 Low concentration of peroxide for treating or preventing vaginal infections |
| 08/04/2004 | EP1441768A1 Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use |
| 08/04/2004 | EP1441767A1 Compositions comprising a photosensitizer and a skin-penetration enhancer and their use in photodynamic treatment |
| 08/04/2004 | EP1441762A1 Rsv gene expression vaccine |
| 08/04/2004 | EP1441752A1 Endophilin homologous proteins involved in the regulation of energy homeostasis |
| 08/04/2004 | EP1441751A1 TARGETING THE REVERSE MODE OF THE Na+ /Ca2+ EXCHANGER FOR THE TREATMENT OF OPTIC NEUROPATHY ASSOCIATED WITH GLAUCOMA AND ISCHEMIC OPTIC NEUROPATHY |
| 08/04/2004 | EP1441745A1 Polyacrylate compositions for use in protecting mucosa |
| 08/04/2004 | EP1441744A2 Improvements in or relating to inhibition of viruses |
| 08/04/2004 | EP1441743A2 Methods for treating ocular neovascular diseases |
| 08/04/2004 | EP1441741A1 Rehydrating formulation |
| 08/04/2004 | EP1441739A1 Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder |
| 08/04/2004 | EP1441738A1 A combination product comprising melagatran and dexamethasone |
| 08/04/2004 | EP1441737A1 Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| 08/04/2004 | EP1441736A2 Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases |
| 08/04/2004 | EP1441735A1 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| 08/04/2004 | EP1441734A1 Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
| 08/04/2004 | EP1441733A1 Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs |
| 08/04/2004 | EP1441732A2 Thiazole derivative and pharmaceutical use thereof |
| 08/04/2004 | EP1441731A1 Pyridone, pyridazone and triazone derivatives as lp-pla2 inhibitors |
| 08/04/2004 | EP1441730A1 Hydrazono-malonitriles |